Accepted Article Lipid Changes During Basal Insulin Peglispro, Insulin Glargine, or NPH Treatment in 6 IMAGINE Trials AUTHORS: H. Ginsberg 1 , B. Cariou 2 , T. Orchard 3 , L. Chen 4 , J. Luo 4 , E.J. Bastyr III 4,5 , J. Bue-Valleskey 4 , A.M. Chang 4 , T. Ivanyi 6 , S.J. Jacober 4 , B.J. Hoogwerf 4 AFFILIATIONS: 1 Irving Institute for Clinical and Translational Research, Columbia University, New York, NY, USA; 2 L’Institut du Thorax, CHU Nantes, Department of Endocrinology, Nantes, France; 3 Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA, USA; 4 Eli Lilly and Company, Indianapolis, IN, USA; 5 Indiana University School of Medicine, Indianapolis, IN, USA 6 Eli Lilly and Company, Budapest, Hungary CORRESPONDING AUTHOR: Byron J. Hoogwerf, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285; (317) 292-6387; fax: (317) 277-8250; hoogwerf_byron_james@lilly.com Abstract Basal insulin peglispro (BIL) is a novel basal insulin with hepato-preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH) from Phase 3 studies in type 1 diabetes (T1D), insulin-naïve type 2 diabetes (T2D) patients, T2D patients on basal insulin only and T2D patients on basal-bolus therapy. BIL treatment had little effect on high-density lipoprotein-cholesterol and low density lipoprotein- This article is protected by copyright. All rights reserved. This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record. Please cite this article as doi: 10.1002/dom.12754